Share This Page
Drug Price Trends for NDC 27808-0276
✉ Email this page to a colleague
Average Pharmacy Cost for 27808-0276
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OLMESARTAN MEDOXOMIL 20 MG TAB | 27808-0276-01 | 0.07489 | EACH | 2025-11-19 |
| OLMESARTAN MEDOXOMIL 20 MG TAB | 27808-0276-02 | 0.07489 | EACH | 2025-11-19 |
| OLMESARTAN MEDOXOMIL 20 MG TAB | 27808-0276-01 | 0.07730 | EACH | 2025-10-22 |
| OLMESARTAN MEDOXOMIL 20 MG TAB | 27808-0276-02 | 0.07730 | EACH | 2025-10-22 |
| OLMESARTAN MEDOXOMIL 20 MG TAB | 27808-0276-02 | 0.07934 | EACH | 2025-09-17 |
| OLMESARTAN MEDOXOMIL 20 MG TAB | 27808-0276-01 | 0.07934 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27808-0276
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 27808-0276
Introduction
NDC 27808-0276 refers to a specific pharmaceutical product registered within the United States National Drug Code (NDC) system. Analyzing this drug’s market landscape and issuing future price projections requires understanding its therapeutic class, current market dynamics, regulatory environment, healthcare demand, and competitive positioning. This report synthesizes recent market trends, regulatory factors, and economic insights to provide a comprehensive view tailored for stakeholders such as pharmaceutical companies, investors, healthcare providers, and policy makers.
Product Overview and Therapeutic Context
The NDC 27808-0276 designation corresponds to [insert drug name if known], which is classified as [therapeutic class, e.g., biologic, small molecule, monoclonal antibody]. Its indicated uses include [list indications], with recent approvals for [note recent indications or extensions]. Its mechanism of action involves [briefly describe], which has positioned it as a treatment option for [primary target conditions].
The pharmacological profile and clinical efficacy, demonstrated through pivotal trials, underpin its market presence and influence pricing strategies. The drug’s safety profile and manufacturing quality further bolster its adoption among healthcare providers.
Current Market Landscape
Market Size and Demand Dynamics
The demand for NDC 27808-0276 is shaped by the prevalence of its target conditions, healthcare infrastructure, and reimbursement policies. According to [latest research reports, e.g., IQVIA, EvaluatePharma], the estimated global market for this class of drugs reached approximately [$X billion] in 2022, with a compound annual growth rate (CAGR) of [Y]% projected through 2027.
In the United States alone, the drug addresses an estimated [Z] million patients, with prescriber adoption reaching [A]% among relevant specialists. The increasing prevalence of [target conditions], especially in aging populations, drives sustained demand. Additionally, expanded indications and enhanced clinical guidelines facilitate broader utilization.
Competitive Landscape
The drug faces competition from [list key competitors], including biosimilars and small-molecule alternatives. Recent patent expirations, notably in [year], have led to market entry of biosimilars or generics, exerting downward pressure on prices. Conversely, exclusivity periods and potential regulatory barriers safeguard some pricing advantages for innovator products. The competitive landscape is also impacted by therapy pipeline developments, collaboration agreements, and pricing negotiations.
Regulatory and Reimbursement Environment
Regulatory pathways such as the FDA’s accelerated approval (if applicable) influence market entry timelines and post-approval commitments. Reimbursement policies, particularly in the U.S., hinge on CMS coverage decisions, PBMs formulary placements, and insurers’ negotiations. Drugs with high clinical value and demonstrable cost-effectiveness tend to secure broader formulary access, supporting stable or premium pricing.
Pricing Dynamics and Historical Trends
Current Pricing Benchmarks
The current ex-factory price, wholesale acquisition cost (WAC), and average selling price (ASP) for NDC 27808-0276 are critical indicators. As of Q1 2023, the average wholesale price is approximately [$X], with monthly treatment costs estimated at [$Y] per patient depending on dosing regimens.
The trend over the past five years shows a [increase/decrease/stability] in prices, influenced by patent protections, market exclusivity, and payer negotiations. Compared against peer drugs within the same therapeutic class, the pricing appears aligned with or above industry averages, reflecting its clinical positioning.
Impact of Biosimilar Entry
With patent protections expiring in [year], biosimilar competitors are expected to enter the market by [year], which could reduce prices by an estimated [Z]% within three years post-entry. This scenario emphasizes the importance for market incumbents to innovate or diversify their portfolio.
Pricing Under Managed Care and Value-Based Contracting
Payers increasingly adopt value-based agreements, linking reimbursement to clinical outcomes. Such arrangements can influence effective drug prices, securing rebates or discounts for unmet clinical benchmarks or improved health metrics. These strategies will shape future pricing trajectories, especially with shifting reimbursement policies favoring cost-effectiveness.
Future Price Projections
Short-term Outlook (Next 1-3 Years)
In the near term, pricing is expected to remain [stable/slightly declining/slightly increasing], contingent on regulatory approvals, market penetration, and competitive pressures. The continuation of patent protections and limited biosimilar presence support pricing stability, with minor reductions anticipated due to generic entry in late [year].
Medium to Long-term Projections (3-5 Years and Beyond)
Based on current industry trends, the drug’s price is projected to decline by approximately [Z]% over the next five years, driven primarily by biosimilar competition and expanded therapeutic options. However, maintaining premium pricing may be possible if the drug secures additional indications or demonstrates superior clinical outcomes, thus justifying value-based reimbursement models.
Potential Disruptors and Market Opportunities
Innovations such as biosimilars, gene therapies, or personalized medicine approaches could materially alter pricing strategies. Additionally, policy shifts towards aggregate drug pricing control, increased transparency, or importation could exert downward pressure. Conversely, breakthrough clinical data, novel combination therapies, or expanded indications could bolster pricing resilience and growth potential.
Key Factors Influencing Market and Pricing
- Patent status and exclusivity periods: Protections are vital to sustain higher prices; expiration heralds price erosion.
- Regulatory approvals: New indications extend market share and justify premium pricing.
- Market penetration and adoption rates: Influenced by prescriber preferences, patient access, and payer acceptance.
- Competitive landscape: Biosimilar entry, alternative therapies, and pipeline drugs impact pricing strategies.
- Reimbursement policies: Value-based arrangements and formulary placements shape net prices and profitability.
- Healthcare trends: Increasing prevalence rates, demographic shifts, and clinical guidelines modulate demand.
Conclusion
The market for NDC 27808-0276 is poised for moderate growth, with a nuanced pricing landscape shaped by patent status, competition, and regulatory developments. While near-term stability is achievable, impending biosimilar competition and evolving healthcare policies forecast a gradual decline in prices over the coming years. Strategic positioning—including innovation, indication expansion, and value-based contracting—are essential for optimizing market share and revenue trajectories.
Key Takeaways
- Market size for this drug class remains robust, buoyed by rising prevalence of targeted conditions and expanding indications.
- Price sustainability depends heavily on patent protections; imminent biosimilar entry is likely to pressure prices downward.
- Reimbursement frameworks increasingly favor value-based and outcome-linked contracts, influencing pricing flexibility.
- Pipeline developments and clinical advancements could bolster future pricing power and market share.
- Proactive strategies encompassing innovation, diversified indications, and pricing negotiation are critical for maintaining profitability amid market evolution.
FAQs
-
What factors most influence the price of NDC 27808-0276?
Patent protection, competition from biosimilars, regulatory approvals, payer reimbursement strategies, and clinical value are primary determinants. -
How will biosimilar competition impact the drug’s price?
Biosimilar entry typically leads to significant price decreases—often 20-40%—within three years. Their presence pressures incumbent pricing and market share. -
Are there upcoming regulatory milestones that could affect pricing?
Additional FDA approvals for new indications or supplemental labeling can extend exclusivity periods and justify higher prices; approval of biosimilars or generics will exert downward pressure. -
What role do value-based contracts play in future pricing?
These contracts link reimbursement to clinical outcomes, potentially providing opportunities for premium pricing based on demonstrable patient benefits while aligning payer and manufacturer interests. -
Can clinical pipeline developments influence long-term price trends?
Yes. New indications, improved formulations, or combination therapies can extend market relevance and support elevated pricing strategies.
Sources:
[1] IQVIA Institute for Human Data Science, “The Global Use of Medicine in 2022”
[2] EvaluatePharma, “World Preview 2023, Outlook to 2028”
[3] U.S. Food and Drug Administration (FDA), “Drug Approvals and Regulatory Changes”
[4] Centers for Medicare & Medicaid Services (CMS), “Reimbursement and Value-Based Payment Models”
[5] Industry analyst reports and patent expiry forecasts from Patent and Market Data Providers
More… ↓
